JP2003500363A5 - - Google Patents

Download PDF

Info

Publication number
JP2003500363A5
JP2003500363A5 JP2000619451A JP2000619451A JP2003500363A5 JP 2003500363 A5 JP2003500363 A5 JP 2003500363A5 JP 2000619451 A JP2000619451 A JP 2000619451A JP 2000619451 A JP2000619451 A JP 2000619451A JP 2003500363 A5 JP2003500363 A5 JP 2003500363A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bpi
protein product
rbpi
middle ear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000619451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/014496 external-priority patent/WO2000071149A2/en
Publication of JP2003500363A publication Critical patent/JP2003500363A/ja
Publication of JP2003500363A5 publication Critical patent/JP2003500363A5/ja
Pending legal-status Critical Current

Links

JP2000619451A 1999-05-24 2000-05-24 滲出を伴う中耳炎を有するヒトにおけるｂｐｉタンパク質産物の治療的使用 Pending JP2003500363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13614899P 1999-05-24 1999-05-24
US60/136,148 1999-05-24
PCT/US2000/014496 WO2000071149A2 (en) 1999-05-24 2000-05-24 Therapeutic uses of bpi protein products in humans with otitis media with effusion

Publications (2)

Publication Number Publication Date
JP2003500363A JP2003500363A (ja) 2003-01-07
JP2003500363A5 true JP2003500363A5 (https=) 2007-07-19

Family

ID=22471532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000619451A Pending JP2003500363A (ja) 1999-05-24 2000-05-24 滲出を伴う中耳炎を有するヒトにおけるｂｐｉタンパク質産物の治療的使用

Country Status (6)

Country Link
US (1) US6670327B1 (https=)
EP (1) EP1181039A2 (https=)
JP (1) JP2003500363A (https=)
AU (1) AU5292300A (https=)
CA (1) CA2373262A1 (https=)
WO (1) WO2000071149A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
AU2005282571A1 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
US20070173463A1 (en) * 2006-01-20 2007-07-26 Brechtelsbauer Paul B Method and composition for treating otitis media
AU2007221150B2 (en) * 2006-02-27 2012-09-20 Ahm Technologies, Inc. Eustachian tube device and method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
JP3040781B2 (ja) * 1987-08-11 2000-05-15 ニューヨーク ユニバーシティ 生物学的に活性な殺菌性／透過性増大蛋白質断片
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
WO1995032728A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of attachment of h. influenzae to human cells
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6350742B1 (en) * 1998-09-11 2002-02-26 Carter-Wallace, Inc. Compositions and methods for treating infections of the ear

Similar Documents

Publication Publication Date Title
Van Watering et al. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production
LT2003107A (en) Pulmonary adminstration of chemically modified insulin
Hill et al. Carcinoembryonic antigen‐related cell adhesion molecule (CEACAM)‐binding recombinant polypeptide confers protection against infection by respiratory and urogenital pathogens
EP1278544A4 (en) ALBUMIN FUSION PROTEINS
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
SE9800836D0 (sv) New Compounds
ATE203165T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndromes
ATE381578T1 (de) Peptide, basierend auf der sequenz des menschlichen lactoferrins und ihre anwendung
ATE215379T1 (de) Antifungaleverfahren und mitteln
Fatemi et al. Comparison of relative TLR‐2 and TLR‐4 expression level of disease and healthy gingival tissue of smoking and non‐smoking patients and periodontally healthy control patients
JP2003500363A5 (https=)
WO2002024883A3 (en) Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
JP2004527551A5 (https=)
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
NO996514L (no) Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom
Fleming et al. Accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice
Roytenberg et al. Thymidine phosphorylase mediates SARS-CoV-2 spike protein enhanced thrombosis in K18-hACE2TG mice
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
NO20026286D0 (no) Nye peptider
JP2005530703A5 (https=)
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
ATE316136T1 (de) Nierenpolycystose-gen
JP2002535282A5 (https=)
ATE324906T1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit